RecruitingPhase 1NCT06046742

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

A Phase I, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Effects of M1-c6v1 for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Sponsor

Guangzhou Virotech Pharmaceutical Co., Ltd.

Enrollment

12 participants

Start Date

Jul 10, 2024

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called M1-c6v1 for people with solid tumor. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.